Interplay between the SAFE and the sphingolipid pathway for cardioprotection.

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Cell Signaling

Background:

• Cardioprotection against ischemia-reperfusion injury (IRI) involves the Survivor Activating Factor Enhancement (SAFE) pathway, including Tumor Necrosis Factor-alpha (TNF-α) and Signal Transducer and Activator of Transcription-3 (STAT-3).
• The sphingolipid signaling pathway, involving sphingosine kinase-1 (SK1) and sphingosine-1 phosphate (S1P), also plays a key role in cardioprotection.

Purpose of the Study:

• To investigate if the cardioprotective effect of exogenous S1P on the SAFE pathway is dependent on SK1 activation.
• To elucidate the role of SK1 in mediating S1P-induced cardioprotection.

Main Methods:

• Isolated cardiomyocytes and hearts from wild-type (WT), TNF-α knockout (KO), and STAT-3 KO mice were subjected to simulated ischemia or IRI.
• Cells and hearts were treated with S1P and/or an SK1 inhibitor (SK1-I).
• Cell viability, infarct size, and SK1 activity were assessed.

Main Results:

• S1P pretreatment reduced cell death in WT mice, but this effect was abolished by SK1-I.
• S1P failed to protect cardiomyocytes or hearts from TNF-α KO and STAT-3 KO mice against simulated ischemia/IRI.
• S1P increased SK1 activity in WT and STAT-3 KO mice, but not in TNF-α KO mice.

Conclusions:

• Sphingosine kinase-1 (SK1) is essential for activating STAT-3 downstream of TNF-α within the SAFE pathway.
• Targeting SK1 presents a potential therapeutic strategy for developing novel cardioprotective treatments against IRI.
• These findings highlight the interplay between sphingolipid metabolism and the SAFE pathway in cardiac protection.